Glaukos Corp (GKOS)

$113.73 +1.45 (1.29%)
Market Cap 6.36B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 388,000
Avg Vol 1,031,646
Day's Range N/A - N/A
Shares Out 57.44M
Stochastic %K 53%
Beta 0.67
Analysts Strong Sell
Price Target $124.07

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
anachartanalyst
anachartanalyst Jan. 2 at 12:01 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1767355272_soc-img.jpg
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 3:01 PM
$GKOS RSI: 62.43, MACD: 4.4196 Vol: 3.50, MA20: 112.16, MA50: 98.51 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 10:30 PM
$GKOS RSI: 72.98, MACD: 5.5829 Vol: 3.92, MA20: 110.40, MA50: 96.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 3:08 PM
UBS has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 140 → 145.
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 2:27 PM
Truist Securities has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 120 → 145.
0 · Reply
ninergizer
ninergizer Dec. 15 at 2:49 PM
$MIST take a look at $GKOS and $ARWR after approval. Dropped and went on 30+% run the next couple of weeks.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 9:02 PM
Citigroup updates rating for Glaukos ( $GKOS ) to Buy, target set at 113 → 125.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 6:58 PM
Needham has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 117 → 125.
0 · Reply
TaoistTrader
TaoistTrader Dec. 8 at 3:24 PM
$GKOS
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 10:39 PM
$GKOS Current Stock Price: $108.51 Contracts to trade: $110 GKOS Dec 19 2025 Call Entry: $3.20 Exit: $4.33 ROI: 35% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on GKOS
Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 16, 2025, 7:00 AM EST - 23 days ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 5:23 PM EST - 5 weeks ago

Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:21 PM EST - 2 months ago

Glaukos Corporation (GKOS) Presents at UBS Global Healthcare Conference 2025 Transcript

Glaukos Announces Participation in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 2 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:06 AM EDT - 2 months ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Glaukos Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 2 months ago

Glaukos Announces Third Quarter 2025 Financial Results

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:10 AM EDT - 2 months ago

US FDA approves Glaukos' new eye therapy

Glaukos Announces FDA Approval of Epioxa™

Oct 20, 2025, 7:00 AM EDT - 2 months ago

Glaukos Announces FDA Approval of Epioxa™

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Oct 8, 2025, 7:00 AM EDT - 3 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Sep 25, 2025, 4:05 PM EDT - 3 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 13, 2025, 7:00 AM EDT - 5 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 5 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 5 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jul 9, 2025, 7:00 AM EDT - 6 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 4:05 PM EDT - 7 months ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 25, 2025, 7:00 AM EDT - 7 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 9 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 9 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 9 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 9 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 9 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 10 months ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 9:12 AM EST - 11 months ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 11 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 10:27 AM EST - 11 months ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 11 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 11 months ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 31, 2024, 8:59 AM EST - 1 year ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 1 year ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 1 year ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 5, 2024, 12:21 PM EST - 1 year ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 1 year ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Jul 10, 2024, 9:05 AM EDT - 1 year ago

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

V HELE LZ SPOT

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results

anachartanalyst
anachartanalyst Jan. 2 at 12:01 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1767355272_soc-img.jpg
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 3:01 PM
$GKOS RSI: 62.43, MACD: 4.4196 Vol: 3.50, MA20: 112.16, MA50: 98.51 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 10:30 PM
$GKOS RSI: 72.98, MACD: 5.5829 Vol: 3.92, MA20: 110.40, MA50: 96.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 3:08 PM
UBS has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 140 → 145.
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 2:27 PM
Truist Securities has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 120 → 145.
0 · Reply
ninergizer
ninergizer Dec. 15 at 2:49 PM
$MIST take a look at $GKOS and $ARWR after approval. Dropped and went on 30+% run the next couple of weeks.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 9:02 PM
Citigroup updates rating for Glaukos ( $GKOS ) to Buy, target set at 113 → 125.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 6:58 PM
Needham has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 117 → 125.
0 · Reply
TaoistTrader
TaoistTrader Dec. 8 at 3:24 PM
$GKOS
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 10:39 PM
$GKOS Current Stock Price: $108.51 Contracts to trade: $110 GKOS Dec 19 2025 Call Entry: $3.20 Exit: $4.33 ROI: 35% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Nov. 28 at 6:10 PM
$GKOS down 29.7% so far this year — poised for a rebound? 📈 🔹 iDose TR launch drives $40M in Q3 sales 🔹 Expanding pipeline with glaucoma, corneal health & retinal disease candidates 🔹 Navigating reimbursement hurdles, but growth strategy in place Opportunity assessment here 👉 https://www.zacks.com/stock/news/2797380/heres-why-you-should-retain-glaukos-stock-in-your-portfolio?cid=sm-stocktwits-2-2797380-body-22787&ADID=SYND_STOCKTWITS_TWEET_2_2797380_BODY_22787
0 · Reply
ZacksResearch
ZacksResearch Nov. 28 at 5:10 PM
Why $GKOS still deserves a spot in your portfolio 👀 The strong launch of iDose TR and a growing pipeline are clear momentum drivers, even as reimbursement hurdles remain part of the road ahead. Solid mix of upside and realism here. Full rundown here 👉 https://www.zacks.com/stock/news/2797380/heres-why-you-should-retain-glaukos-stock-in-your-portfolio?cid=sm-stocktwits-2-2797380-teaser-22785&ADID=SYND_STOCKTWITS_TWEET_2_2797380_TEASER_22785
0 · Reply
Estimize
Estimize Nov. 24 at 12:01 PM
Wall St is expecting -0.21 EPS for $GKOS Q4 [Reporting 02/19 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 9:44 PM
$GIB $GILD $GKOS $GLNG $GLW
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Nov. 7 at 10:21 PM
$GKOS $CYBR $CAMT $VEEV Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off Brown Capital Management sold 376,359 shares of Glaukos for $34.6M in Q3. The sale represented about 1.4% of the fund's 13F assets. It retains 762,760 shares valued at $62.2M.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 11:48 PM
$GKOS Share Price: $81.75 Contract Selected: Apr 17, 2026 $80 Calls Buy Zone: $10.71 – $13.23 Target Zone: $17.21 – $21.04 Potential Upside: 52% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 6 at 5:38 PM
$GKOS Brown Capital’s $34.6M sale didn’t shake confidence—Glaukos’ glaucoma implants, 22% revenue growth, and $475M sales forecast fuel optimism. https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 9:48 PM
$GIB $GILD $GKOS $GLNG $GLW 🔥
0 · Reply
TipRanks
TipRanks Nov. 4 at 11:11 AM
Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner https://www.tipranks.com/news/article/beaten-down-by-35-plus-analysts-say-these-2-oversold-stocks-are-poised-to-turn-the-corner $XNCR $GKOS
0 · Reply
ninergizer
ninergizer Oct. 30 at 9:19 PM
$INVA This is next, we hit $CRNX and $GKOS 25 % plus. Do your DD. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 7:56 PM
$GKOS close my eyes! 👀
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 6:14 PM
$GKOS Is time to pull back yet?
0 · Reply